HR2767

The BRAIN Act (HR2767) was introduced on April 9, 2025, by Rep. Fitzpatrick (R-PA) with 48 cosponsors and was referred to the House Committee on Energy and Commerce. It is an early-stage authorization bill in the 119th Congress with a companion bill (S1330) in the Senate. The bill establishes several programmatic structures: fostering transparency of biospecimen collections for brain cancer research (Section 3), creating a Glioblastoma Therapeutics Network and team science awards for brain tumor cellular immunotherapy including CAR-T (Section 4), launching a national public awareness campaign for cancer clinical trials and biomarker testing (Section 5), pilot programs for brain tumor survivor care (Section 6), and directing FDA to issue guidance on brain tumor patient access to clinical trials (Section 7). Critically, the bill text contains no authorized funding amount, no appropriation, and no revenue-generating mechanisms. This is purely an authorization bill that sets policy direction and creates programmatic frameworks. Actual funding would require a separate appropriations process, which has not occurred. The legislative path forward is lengthy: the bill must pass through the House Energy and Commerce Committee, receive a floor vote in the House, pass the Senate (where companion S1330 has been referred to HELP committee), and then be signed into law before any programmatic implementation can begin. Structural winners, if funding were eventually appropriated, would include genomic sequencing and liquid biopsy companies like Illumina, Guardant Health, and Exact Sciences, as the bill's emphasis on biospecimen analysis and biomarker testing for clinical trials would create incremental demand for their services. However, without funding authorization or even appropriation, these are purely speculative. The companies that could benefit most—pure-play neuro-oncology diagnostics firms—largely do not trade publicly on US exchanges. No real market data is provided, so no price trend analysis is possible. The competitive landscape in brain tumor diagnostics and therapeutics is dominated by academic medical centers and private biotech firms, not large publicly traded companies. For the tickers listed, the revenue impact is marginal (sub-$3M annually) and highly uncertain. Timeline: given the bill's early stage, multiple committee markups, floor votes in both chambers, and eventual appropriations process are required. Even under fast-track assumptions, material market impact is 12-24 months away, if ever realized.